Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

2010-2020 enrolled

2020+ enrolled

Remaining of 2020+ enrollment goal

Enrollment complete

Parkinson's Disease Cohort

2020+ Enrollment Goal: 1,010



Prodromal Cohort

2020+ Enrollment Goal: 2,220



Healthy Controls Cohort

2020+ Enrollment Goal: 120



Last update: January 5, 2021

More about study cohorts >

A Landmark Study of Parkinson’s Disease

PPMI is a landmark observational study to better define and measure Parkinson’s disease to speed therapeutic development. PPMI makes its data set and biorepository — the most robust in Parkinson’s to date — available to academia and industry to accelerate breakthroughs.

Launched in 2010, PPMI has gathered longitudinal data from more than 1,400 individuals at 33 clinical sites in 11 countries. The study is now recruiting a larger and more diverse group of individuals — de novo Parkinson’s, control volunteers and at-risk populations — who can contribute to a more detailed look into the way the disease develops and changes over time. PPMI will grow to 50+ sites and follow more than 4,000 participants.

PPMI is sponsored by The Michael J. Fox Foundation for Parkinson’s Research and supported by various industry, non-profit and private partners.

This website is primarily for researchers and study partners. Interested potential participants can learn more at michaeljfox.org/ppmi.


Interview on RNA in PPMI with Dr. Van Keuren-Jensen

Today, we will be asking Dr. Van-Keuren Jensen a few questions about RNA and hearing her insight as to why this vital element is something, we are focusing on in the Parkinson?s Progression Markers Initiative (PPMI). Dr. Van Keuren-Jensen received her Ph.D. from Cold Spring Harbor Laboratory in New York, where she studied the role […]

Recent Findings in PPMI

by Krishna Knabe The Michael J. Fox Foundation A group of authors led by PPMI’s principal investigator, Dr. Kenneth Marek, published baseline data from the study in the Annals of Clinical and Translational Neurology. The paper includes detailed biomarker signatures on the initial volunteer groups, which include patients with Parkinson’s disease, healthy controls and those who […]

Learn More